About Us

We are a clinical-stage biopharmaceutical company dedicated to the discovery and development of therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Our team finds meaning in making purposeful connections as we seek to bring forward groundbreaking therapies for patients who need them.

Leadership

Norbert Bischofberger, Ph.D.

President & Chief Executive Officer

Yasir Al-Wakeel, BM BCh

Chief Financial Officer and Head of Corporate Development

Barbara Kosacz

Chief Operating Officer and General Counsel

Jorge DiMartino M.D., Ph.D.

Chief Medical Officer and Executive Vice President, Clinical Development

Christopher Dinsmore, Ph.D.

Chief Scientific Officer

Allison Frisbee

Senior Vice President, Deputy General Counsel

Charles Lin, Ph.D.

Senior Vice President, Biology

Elizabeth Olek, DO, MPH

Senior Vice President, Clinical Development

Wes Trotter, Ph.D.

Senior Vice President, Drug Discovery

Anders Vinther, Ph.D.

Senior Vice President, Pharmaceutical Development and Manufacturing

Kathryn Adamiak

Vice President, Finance

Sarah Connors

Vice President of Investor Relations and Corporate Communications

Richard Cutler, Ph.D.

Vice President, Clinical Science

Pavan Kumar, Ph.D.

Vice President, Translational Development

Rocio Martin Hoyos

Vice President, Commercial Strategy

Matt Smith

Vice President, U.S./Global Market Access and Reimbursement

Board of Directors

Arie Belldegrun, M.D.

Chair

Norbert Bischofberger, Ph.D.

President & Chief Executive Officer

Roshawn Blunt

Roger Dansey, M.D.

Marianne De Backer, Ph.D.

Joshua Kazam

Elena Ridloff, CFA

Katherine Vega Stultz

David Tanen

Taiyin Yang, Ph.D.

Scientific Advisory Board

Owen Witte, M.D.

Scientific Advisory Board Chair

Myles Brown, M.D.

Dana-Farber Cancer Institute
Brigham and Women’s Hospital
Harvard Medical School

Robert Eisenman, Ph.D.

Fred Hutchinson Cancer Research Center/
University of Washington School of Medicine

Angela Koehler, Ph.D.

Scientific Founder
Assistant Professor,
Koch Institute for Integrative Cancer Research (MIT)